Rhythm Pharmaceuticals, Inc. announced that a new International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code for Bardet-Biedl Syndrome (BBS) was approved by the Centers for Disease Control and Prevention (CDC). The new code, Q87.83 Bardet-Biedl syndrome (BBS), takes effect Oct. 1, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.21 USD | -1.50% | -7.06% | -21.23% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.23% | 2.24B | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- RYTM Stock
- News Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome